Literature DB >> 11533167

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.

D O'Hagan1, M Singh, M Ugozzoli, C Wild, S Barnett, M Chen, M Schaefer, B Doe, G R Otten, J B Ulmer.   

Abstract

The effectiveness of cationic microparticles with adsorbed DNA at inducing immune responses was investigated in mice, guinea pigs, and rhesus macaques. Plasmid DNA vaccines encoding human immunodeficiency virus (HIV) Gag and Env adsorbed onto the surface of cationic poly(lactide-coglycolide) (PLG) microparticles were shown to be substantially more potent than corresponding naked DNA vaccines. In mice immunized with HIV gag DNA, adsorption onto PLG increased CD8(+) T-cell and antibody responses by approximately 100- and approximately 1,000-fold, respectively. In guinea pigs immunized with HIV env DNA adsorbed onto PLG, antibody responses showed a more rapid onset and achieved markedly higher enzyme-linked immunosorbent assay and neutralizing titers than in animals immunized with naked DNA. Further enhancement of antibody responses was observed in animals vaccinated with PLG/DNA microparticles formulated with aluminum phosphate. The magnitude of anti-Env antibody responses induced by PLG/DNA particles was equivalent to that induced by recombinant gp120 protein formulated with a strong adjuvant, MF-59. In guinea pigs immunized with a combination vaccine containing HIV env and HIV gag DNA plasmids on PLG microparticles, substantially superior antibody responses were induced against both components, as measured by onset, duration, and titer. Furthermore, PLG formulation overcame an apparent hyporesponsiveness of the env DNA component in the combination vaccine. Finally, preliminary data in rhesus macaques demonstrated a substantial enhancement of immune responses afforded by PLG/DNA. Therefore, formulation of DNA vaccines by adsorption onto PLG microparticles is a powerful means of increasing vaccine potency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533167      PMCID: PMC114472          DOI: 10.1128/JVI.75.19.9037-9043.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics.

Authors:  E Walter; K Moelling; J Pavlovic; H P Merkle
Journal:  J Control Release       Date:  1999-09-20       Impact factor: 9.776

2.  Biological activity of rhBMP-2 released from PLGA microspheres.

Authors:  J B Oldham; L Lu; X Zhu; B D Porter; T E Hefferan; D R Larson; B L Currier; A G Mikos; M J Yaszemski
Journal:  J Biomech Eng       Date:  2000-06       Impact factor: 2.097

3.  Quantitative analysis of the immunopotency of genetically transfected dendritic cells.

Authors:  L Timares; A Takashima; S A Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

4.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells.

Authors:  M A Chattergoon; T M Robinson; J D Boyer; D B Weiner
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

5.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells.

Authors:  E Manickan; S Kanangat; R J Rouse; Z Yu; B T Rouse
Journal:  J Leukoc Biol       Date:  1997-02       Impact factor: 4.962

7.  Increased DNA vaccine delivery and immunogenicity by electroporation in vivo.

Authors:  G Widera; M Austin; D Rabussay; C Goldbeck; S W Barnett; M Chen; L Leung; G R Otten; K Thudium; M J Selby; J B Ulmer
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

8.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

9.  Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines.

Authors:  S M Barratt-Boyes; M I Zimmer; L A Harshyne; E M Meyer; S C Watkins; S Capuano; M Murphey-Corb; L D Falo; A D Donnenberg
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

10.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

View more
  35 in total

1.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance.

Authors:  Manmohan Singh; Mildred Ugozzoli; Maylene Briones; Jina Kazzaz; Elawati Soenawan; Derek T O'Hagan
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

Review 4.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

5.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

6.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

8.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

9.  Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain.

Authors:  Erin D Milligan; Ryan G Soderquist; Stephanie M Malone; John H Mahoney; Travis S Hughes; Stephen J Langer; Evan M Sloane; Steven F Maier; Leslie A Leinwand; Linda R Watkins; Melissa J Mahoney
Journal:  Neuron Glia Biol       Date:  2006-11

10.  Prospects for control of emerging infectious diseases with plasmid DNA vaccines.

Authors:  Ronald B Moss
Journal:  J Immune Based Ther Vaccines       Date:  2009-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.